• 1
    Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergic drugs. BMJ 1991;302:265269.
  • 2
    Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001;107: 8793.
  • 3
    Bodtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy – a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002;57:297305.
  • 4
    Arvidsson MB, Lowhagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002;109:777783.
  • 5
    Togias A. Mechanisms of nose-lung interaction. Allergy 1999;54(Suppl. 57):94105.
  • 6
    Simons FE. Allergic rhinobronchitis: the asthma-allergic rhinitis link. J Allergy Clin Immunol 1999;104:534540.
  • 7
    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108(5 Suppl.):S147S334.
  • 8
    Johnstone DE, Dutton A. The value of hyposensitization therapy for bronchial asthma in children – a 14-year study. Pediatrics 1968;42:793802.
  • 9
    Moller C, Dreborg S, Ferdousi HA, Halken S, Host A, Jacobsen L et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251256.
  • 10
    Moller C, Bjorksten B, Nilsson G, Dreborg S. The precision of the conjunctival provocation test. Allergy 1984;39:3741.
  • 11
    Matthys H, Knoch M, Eltschka R. A new aerosol device for bronchial provocation tests. Respiration 1993; 60:343350.
  • 12
    ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials. International conference on harmonisation E9 expert working group. Stat Med 1999;18:19051942.
  • 13
    Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988;43:523529.
  • 14
    Jacobsen L, Nuchel PB, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardized tree pollen extracts. IV. Results from long-term (6-year) follow-up. Allergy 1997;52:914920.
  • 15
    Hedlin G, Heilborn H, Lilja G, Norrlind K, Pegelow KO, Schou C et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96:879885.
  • 16
    Durham SR, Walker SM, Varga EM, Jacobson MR, O'Brien F, Noble W et al. Long-term clinical efficacy of grass-pollen immunotherapy (see comments). N Engl J Med 1999;341:468475.
  • 17
    Des Roches A, Paradis L, Knani J, Hejjeoui A, Dhivert H, Chanez P et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. V. Duration of the efficacy of immunotherapy after its cessation. J Allergy 1996;51:430433.
  • 18
    Bauer CP. Untersuchung zur Asthmaprävention durch die spezifische Immuntherapie bei Kindern. Allergologie 1993;16:468.
  • 19
    Grembiale RD, Camporota L, Naty S, Tranfa CM, Djukanovic R, Marsico SA. Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness. Am J Respir Crit Care Med 2000;162:20482052.
  • 20
    Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De ME et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851857.
  • 21
    Ulrik CS, Backer V. Longitudinal determinants of bronchial responsiveness to inhaled histamine. Chest 1998;113:973979.
  • 22
    Burrows B, Sears MR, Flannery EM, Herbison GP, Holdaway MD, Silva PA. Relation of the course of bronchial responsiveness from age 9 to age 15 to allergy. Am J Respir Crit Care Med 1995;152:13021308.